Slideshows Images Quizzes


Last reviewed on RxList: 8/7/2017
Evoclin Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Last reviewed on RxList 8/07/2017

Evoclin (clindamycin phosphate) is an antibiotic used to treat severe acne. Evoclin is available in generic form. Common side effects of Evoclin include:

  • application site reactions (redness, itching, dryness of treated skin areas, burning, irritation, or pain)
  • hives
  • abdominal pain or discomfort
  • hypersensitivity
  • rash
  • nausea
  • scaly skin
  • dizziness

Tell your doctor if you experience serious side effects of Evoclin including:

  • severe redness
  • itching
  • dryness of treated skin areas
  • watery or bloody diarrhea

It is recommended to apply Evoclin to the affected areas once daily after skin is washed and dried. Evoclin may interact with erythromycin. Discontinue use of Evoclin and contact your doctor immediately if you experience severe or bloody diarrhea, or colitis. Avoid contact of Evoclin with eyes, mouth, lips, other mucous membranes, and broken skin. If contact occurs rinse thoroughly with water. Caution should be taken if you are pregnant or breastfeeding while using Evoclin.

Our Evoclin (clindamycin phosphate) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Evoclin Consumer Information

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Although the risk of serious side effects is low when clindamycin is applied to the skin, side effects can occur if the medication is absorbed into your bloodstream.

Stop using clindamycin topical and call your doctor at once if you have any of these serious side effects:

  • severe redness, itching, or dryness of treat skin areas; or
  • diarrhea that is watery or bloody.

Less serious side effects may include:

  • mild burning or itching;
  • mild dryness of treated skin; or
  • redness or other irritation.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Evoclin (Clindamycin Phosphate)

Evoclin Professional Information


Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

A total of 439 subjects with mild to moderate acne vulgaris were treated once daily for 12 weeks with EVOCLIN Foam.

The incidence of adverse reactions occurring in ≥1% of the subjects in clinical trials comparing EVOCLIN Foam and its vehicle is presented in Table 1.

Table 1: Adverse Reactions Occurring in ≥1% of Subjects

Adverse Reactions Number (%) of Subjects
N = 439
Vehicle Foam
N = 154
Headache 12 (3%) 1 (1%)
Application site burning 27 (6%) 14 (9%)
Application site pruritus 5 (1%) 5 (3%)
Application site dryness 4 (1%) 5 (3%)
Application site reaction, not otherwise specified 3 (1%) 4 (3%)

In a contact sensitization study, none of the 203 subjects developed evidence of allergic contact sensitization to EVOCLIN Foam.

Postmarketing Experience

The following adverse reactions have been identified during post approval use of EVOCLIN Foam: application site pain, application site erythema, diarrhea, urticaria, abdominal pain, hypersensitivity, rash, abdominal discomfort, nausea, seborrhea, application site rash, dizziness, pain of skin, colitis (including pseudomembranous colitis), and hemorrhagic diarrhea. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Abdominal pain and gastrointestinal disturbances, as well as gram-negative folliculitis, have also been reported in association with the use of topical formulations of clindamycin. Orally and parenterally administered clindamycin have been associated with severe colitis, which may end fatally.

Read the entire FDA prescribing information for Evoclin (Clindamycin Phosphate)

Related Resources for Evoclin

© Evoclin Patient Information is supplied by Cerner Multum, Inc. and Evoclin Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors